Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Coherus Oncology, Inc. stock logo
CHRS
Coherus Oncology
$0.80
+0.7%
$0.83
$0.66
$2.43
$92.86M0.862.67 million shs679,404 shs
Cellectis S.A. stock logo
CLLS
Cellectis
$1.59
-3.9%
$1.49
$1.10
$2.43
$88.09M2.91143,032 shs37,406 shs
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
$143.01
+1.2%
$138.57
$122.80
$219.34
$4.13B0.67287,155 shs168,281 shs
Passage Bio, Inc. stock logo
PASG
Passage Bio
$0.46
+13.5%
$0.37
$0.26
$1.33
$28.65M1.67375,068 shs499,654 shs
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
$33.24
-0.1%
$33.32
$27.66
$121.06
$4.29B1.191.47 million shs474,884 shs
5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Coherus Oncology, Inc. stock logo
CHRS
Coherus Oncology
+0.74%+9.34%+2.69%+2.46%-42.37%
Cellectis S.A. stock logo
CLLS
Cellectis
-3.94%+7.82%+8.56%+37.83%-22.68%
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
+1.17%+0.30%+9.24%-16.51%-19.46%
Passage Bio, Inc. stock logo
PASG
Passage Bio
+13.46%+39.70%-7.62%+35.59%-48.30%
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
-0.11%+1.08%-4.08%+5.17%-56.42%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Coherus Oncology, Inc. stock logo
CHRS
Coherus Oncology
3.7583 of 5 stars
3.31.00.04.50.62.50.6
Cellectis S.A. stock logo
CLLS
Cellectis
2.5398 of 5 stars
3.53.00.00.00.62.50.6
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
4.533 of 5 stars
3.51.00.04.72.32.51.9
Passage Bio, Inc. stock logo
PASG
Passage Bio
2.9184 of 5 stars
3.53.00.00.01.41.71.3
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
1.7857 of 5 stars
3.61.00.00.02.01.70.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Coherus Oncology, Inc. stock logo
CHRS
Coherus Oncology
2.67
Moderate Buy$4.68484.69% Upside
Cellectis S.A. stock logo
CLLS
Cellectis
3.00
Buy$4.00152.37% Upside
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
3.00
Buy$211.1347.63% Upside
Passage Bio, Inc. stock logo
PASG
Passage Bio
3.00
Buy$7.501,526.90% Upside
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
3.10
Buy$136.50310.71% Upside

Current Analyst Ratings Breakdown

Latest CHRS, KRYS, PASG, PCVX, and CLLS Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/24/2025
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$240.00
6/24/2025
Passage Bio, Inc. stock logo
PASG
Passage Bio
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$6.00
5/16/2025
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$215.00 ➝ $155.00
5/13/2025
Cellectis S.A. stock logo
CLLS
Cellectis
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$5.00 ➝ $4.00
5/7/2025
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$195.00 ➝ $189.00
5/7/2025
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$219.00 ➝ $219.00
5/6/2025
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$240.00 ➝ $240.00
4/29/2025
Coherus Oncology, Inc. stock logo
CHRS
Coherus Oncology
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$7.00 ➝ $7.00
4/28/2025
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$221.00 ➝ $240.00
4/24/2025
Coherus Oncology, Inc. stock logo
CHRS
Coherus Oncology
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral$1.50 ➝ $1.05
4/22/2025
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight
(Data available from 7/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Coherus Oncology, Inc. stock logo
CHRS
Coherus Oncology
$266.96M0.35$0.29 per share2.73($1.14) per share-0.70
Cellectis S.A. stock logo
CLLS
Cellectis
$49.22M1.79N/AN/A$2.36 per share0.67
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
$290.52M14.23$4.69 per share30.48$32.90 per share4.35
Passage Bio, Inc. stock logo
PASG
Passage Bio
N/AN/AN/AN/A$0.99 per shareN/A
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
N/AN/AN/AN/A$26.52 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Coherus Oncology, Inc. stock logo
CHRS
Coherus Oncology
$28.51M-$1.13N/AN/AN/A-66.30%N/A-26.51%8/6/2025 (Estimated)
Cellectis S.A. stock logo
CLLS
Cellectis
-$36.76M-$0.86N/AN/AN/A-114.82%-62.55%-21.19%8/5/2025 (Estimated)
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
$89.16M$4.1634.3814.19N/A37.17%14.64%13.28%8/4/2025 (Estimated)
Passage Bio, Inc. stock logo
PASG
Passage Bio
-$64.77M-$1.02N/AN/AN/AN/A-93.59%-59.65%8/14/2025 (Estimated)
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
-$463.93M-$3.99N/AN/AN/AN/A-17.12%-16.26%8/5/2025 (Estimated)

Latest CHRS, KRYS, PASG, PCVX, and CLLS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/14/2025Q1 2025
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
-$1.02-$1.04-$0.02-$1.04N/AN/A
5/13/2025Q1 2025
Passage Bio, Inc. stock logo
PASG
Passage Bio
-$0.24-$0.25-$0.01-$0.25N/AN/A
5/12/2025Q1 2025
Coherus Oncology, Inc. stock logo
CHRS
Coherus Oncology
-$0.31-$0.35-$0.04-$0.49$59.79 million$7.60 million
5/12/2025Q1 2025
Cellectis S.A. stock logo
CLLS
Cellectis
-$0.1540-$0.18-$0.0260-$0.18$12.71 million$12.03 million
5/6/2025Q1 2025
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
$1.38$1.20-$0.18$1.20$98.66 million$88.18 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Coherus Oncology, Inc. stock logo
CHRS
Coherus Oncology
N/AN/AN/AN/AN/A
Cellectis S.A. stock logo
CLLS
Cellectis
N/AN/AN/AN/AN/A
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
N/AN/AN/AN/AN/A
Passage Bio, Inc. stock logo
PASG
Passage Bio
N/AN/AN/AN/AN/A
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Coherus Oncology, Inc. stock logo
CHRS
Coherus Oncology
N/A
1.22
1.20
Cellectis S.A. stock logo
CLLS
Cellectis
0.44
1.67
1.67
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
N/A
9.65
9.27
Passage Bio, Inc. stock logo
PASG
Passage Bio
N/A
3.74
3.74
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
N/A
17.70
17.70

Institutional Ownership

CompanyInstitutional Ownership
Coherus Oncology, Inc. stock logo
CHRS
Coherus Oncology
72.82%
Cellectis S.A. stock logo
CLLS
Cellectis
63.90%
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
86.29%
Passage Bio, Inc. stock logo
PASG
Passage Bio
53.48%
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
96.78%

Insider Ownership

CompanyInsider Ownership
Coherus Oncology, Inc. stock logo
CHRS
Coherus Oncology
8.08%
Cellectis S.A. stock logo
CLLS
Cellectis
16.41%
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
13.70%
Passage Bio, Inc. stock logo
PASG
Passage Bio
5.00%
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
3.10%
CompanyEmployeesShares OutstandingFree FloatOptionable
Coherus Oncology, Inc. stock logo
CHRS
Coherus Oncology
330115.93 million106.57 millionOptionable
Cellectis S.A. stock logo
CLLS
Cellectis
29055.58 million46.46 millionOptionable
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
21028.90 million24.94 millionOptionable
Passage Bio, Inc. stock logo
PASG
Passage Bio
13062.15 million59.04 millionOptionable
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
160129.00 million125.01 millionOptionable

Recent News About These Companies

Vaxcyte: Sentiment Is Pushing The Shares Down
Vaxcyte appoints new independent director

New MarketBeat Followers Over Time

Media Sentiment Over Time

Coherus Oncology stock logo

Coherus Oncology NASDAQ:CHRS

$0.80 +0.01 (+0.74%)
Closing price 07/3/2025 03:39 PM Eastern
Extended Trading
$0.78 -0.03 (-3.12%)
As of 07/3/2025 04:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of cancer treatments primarily in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel PD-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype G1 (IgG1) monoclonal antibody targeting interleukin 27. It is also developing CHS-114, an investigational highly specific human afucosylated IgG1 monoclonal antibody selectively targeting CCR8, a chemokine receptor highly expressed on Treg cells in the tumor microenvironment (TME); and CHS-1000, an antibody targeting human ILT4 designed to improve anti-PD-1 clinical benefit by transforming an unfavorable TME to a more favorable TME. In addition, the company's licensed immuno-oncology programs include NZV930, an antibody designed to inhibit cluster of differentiation 73; and GSK4381562, an antibody targeting CD112R for the treatment of solid tumors. Further, it offers YUSIMRY, a biosimilar to Humira for the treatment of patients with inflammatory diseases characterized by increased production of tumor necrosis factor (TNF) in the body, including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, psoriasis, and ulcerative colitis. It collaboration agreement with Junshi Biosciences for the co-development and commercialization of toripalimab; agreement with Surface and Adimab LLC; license agreements with Bioeq AG and Genentech, Inc., as well as Vaccinex, Inc.; and out-licensing agreement with Novartis Institutes for Biomedical Research, Inc. and GlaxoSmithKline Intellectual Property No. 4 Limited. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.

Cellectis stock logo

Cellectis NASDAQ:CLLS

$1.58 -0.07 (-3.94%)
As of 07/3/2025 03:11 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma. It also develops UCART22 to treat B-cell acute lymphoblastic leukemia; UCARTCS1 and ALLO-605 for the treatment of multiple myeloma; ALLO-316 for renal cell carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART 20x22 for relapsed or refractory B-Cell NHL. The company has strategic alliances with Allogene Therapeutics, Inc. and Les Laboratoires Servier; research collaboration and exclusive license agreement with Iovance Biotherapeutics; and collaboration and license agreement with Cytovia, as well as a collaboration agreement with AstraZeneca to develop novel cell and gene therapy candidate products. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.

Krystal Biotech stock logo

Krystal Biotech NASDAQ:KRYS

$143.01 +1.66 (+1.17%)
Closing price 07/3/2025 03:17 PM Eastern
Extended Trading
$146.50 +3.49 (+2.44%)
As of 07/3/2025 04:45 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.

Passage Bio stock logo

Passage Bio NASDAQ:PASG

$0.46 +0.05 (+13.46%)
Closing price 07/3/2025 03:36 PM Eastern
Extended Trading
$0.46 0.00 (-0.22%)
As of 07/3/2025 04:46 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; and PBKR03, a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease. The company develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and other program for huntington's disease. It has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. Passage Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.

Vaxcyte stock logo

Vaxcyte NASDAQ:PCVX

$33.24 -0.04 (-0.11%)
As of 07/3/2025 03:51 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.